ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
批准号:
10923773
负责人:
VILASACK THAMMAVONGSA
金额:
$62.29万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-21 至 2024-09-20
关键词:
Advanced DevelopmentAnimal ModelBacterial Drug ResistanceClinicalCommunicable DiseasesContractsDisease OutbreaksEmerging Communicable DiseasesFormulationIndividualSafetyStaphylococcus aureusStaphylococcus aureus infectionToxicologyVaccinesbiodefenseefficacy evaluationefficacy testingimmunogenicitymanufactureresponsestability testingvaccine candidatevaccine development
中文摘要
支持候选产品的高级开发,用于故意释放或应对生物防御或自然发生的传染病和新发传染病爆发。该合同可支持单个疫苗组分的配制和生产,以及动物模型中的稳定性试验、非临床免疫原性和有效性试验、IND启用GLP毒理学、IND提交以及临床安全性和有效性评价。
英文摘要
To support the advanced development of candidate products for use following the intentional release of or in response to biodefense or naturally occurring outbreaks of infectious diseases and emerging infectious diseases. This contract may support formulation and manufacture of the individual vaccine components, as well as stability testing, nonclinical immunogenicity and efficacy testing in animal models, IND enabling GLP toxicology, submission of an IND and clinical safety and efficacy evaluation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
-
批准号:10710588
-
项目类别:
-
资助金额:$111.91万
-
财政年份:2022
-
负责人:VILASACK THAMMAVONGSA
-
依托单位:
海外基金